NASDAQ:FMI - Foundation Medicine Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$137.00 0.00 (0.00 %)
(As of 08/17/2018 04:00 PM ET)
Previous Close$137.00
Today's RangeN/A
52-Week Range$31.70 - $137.20
VolumeN/A
Average Volume621,352 shs
Market Capitalization$5.09 billion
P/E Ratio-30.44
Dividend YieldN/A
Beta-0.1
Foundation Medicine logoFoundation Medicine, Inc. provides various molecular information products in the United States. The company's molecular information platform includes proprietary methods and algorithms to analyze specimens across various types of cancer, as well as for incorporating that information into clinical care; and offers genomic insights about each patient's individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted therapies and immunotherapies. It provides clinical products, such as FoundationOne for solid tumors; FoundationOne Heme for blood-based cancers, or hematologic malignancies, including leukemia, lymphoma, and sarcomas; Foundation Assay for Circulating Tumor; FoundationFocus CDxBRCA, a diagnostic assay to aid in identifying women with ovarian cancer; and FoundationOne CDx, a diagnostic assay for solid tumors. The company also offers FoundationCORE, a knowledgebase to publish scientific and medical advances, and foster relationships throughout the oncology community. In addition, it has strategic collaboration agreements with F. Hoffmann-La Roche Ltd.; and Genentech, Inc. Foundation Medicine, Inc. has a collaboration with The European Organisation for Research and Treatment of Cancer to advance precision medicine using comprehensive genomic profiling to facilitate clinical trial enrollment. It also has a three-party collaboration agreement with F. Hoffmann-La Roche Ltd and DIAN Diagnostics Group, Co., Ltd. to integrate the company's comprehensive genomic profiling assays into clinical patient care in mainland China. The company was founded in 2009 and is headquartered in Cambridge, Massachusetts. Foundation Medicine, Inc. is a subsidiary of Roche Holdings, Inc.

Receive FMI News and Ratings via Email

Sign-up to receive the latest news and ratings for FMI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FMI
CUSIPN/A
Phone617-418-2200

Debt

Debt-to-Equity Ratio4.76
Current Ratio2.27
Quick Ratio1.98

Price-To-Earnings

Trailing P/E Ratio-30.44
Forward P/E Ratio-31.07
P/E GrowthN/A

Sales & Book Value

Annual Sales$152.90 million
Price / Sales33.28
Cash FlowN/A
Price / CashN/A
Book Value$0.87 per share
Price / Book157.47

Profitability

EPS (Most Recent Fiscal Year)($4.50)
Net Income$-161,460,000.00
Net Margins-84.96%
Return on Equity-299.63%
Return on Assets-94.81%

Miscellaneous

Employees662
Outstanding Shares37,140,000
Market Cap$5.09 billion

Foundation Medicine (NASDAQ:FMI) Frequently Asked Questions

What is Foundation Medicine's stock symbol?

Foundation Medicine trades on the NASDAQ under the ticker symbol "FMI."

How were Foundation Medicine's earnings last quarter?

Foundation Medicine Inc (NASDAQ:FMI) posted its earnings results on Wednesday, May, 2nd. The company reported ($1.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.10) by $0.08. The firm earned $52.84 million during the quarter, compared to analysts' expectations of $44.99 million. Foundation Medicine had a negative return on equity of 299.63% and a negative net margin of 84.96%. The company's revenue was up 100.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.31) earnings per share. View Foundation Medicine's Earnings History.

What price target have analysts set for FMI?

4 analysts have issued 12 month price targets for Foundation Medicine's shares. Their forecasts range from $73.00 to $90.00. On average, they anticipate Foundation Medicine's stock price to reach $81.00 in the next year. This suggests that the stock has a possible downside of 40.9%. View Analyst Price Targets for Foundation Medicine.

What is the consensus analysts' recommendation for Foundation Medicine?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Foundation Medicine in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Foundation Medicine.

Are investors shorting Foundation Medicine?

Foundation Medicine saw a decrease in short interest during the month of July. As of July 31st, there was short interest totalling 574,544 shares, a decrease of 51.7% from the July 13th total of 1,190,721 shares. Based on an average daily volume of 713,842 shares, the short-interest ratio is presently 0.8 days. Approximately 3.2% of the company's stock are sold short. View Foundation Medicine's Current Options Chain.

Who are some of Foundation Medicine's key competitors?

Who are Foundation Medicine's key executives?

Foundation Medicine's management team includes the folowing people:
  • Mr. Troy Cox, CEO, Pres & Director (Age 54)
  • Mr. Michael Doherty, Head of Product Devel. (Age 59)
  • Mr. Jason Ryan, Chief Financial Officer (Age 44)
  • Mr. Konstantin Fiedler, Chief Operating Officer (Age 52)
  • Mr. Tom Godden, Chief Information Officer

Has Foundation Medicine been receiving favorable news coverage?

Media coverage about FMI stock has been trending positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Foundation Medicine earned a media and rumor sentiment score of 0.43 on Accern's scale. They also assigned news stories about the company an impact score of 48.71 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Foundation Medicine.

Who are Foundation Medicine's major shareholders?

Foundation Medicine's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.95%), Gilder Gagnon Howe & Co. LLC (3.60%), Chevy Chase Trust Holdings Inc. (2.19%), Baillie Gifford & Co. (1.09%), Morgan Stanley (1.03%) and Gabelli Funds LLC (0.79%). Company insiders that own Foundation Medicine stock include David Daly, Evan/ Fa Jones, Jason Ryan, Konstantin Fiedler, Krishna Yeshwant, Michael J Doherty, Michael J Pellini, Robert W Hesslein, Roche Holdings Inc, Steven J Kafka, Troy Cox and Vincent A Miller. View Institutional Ownership Trends for Foundation Medicine.

Which major investors are selling Foundation Medicine stock?

FMI stock was sold by a variety of institutional investors in the last quarter, including Oppenheimer & Co. Inc., Boston Advisors LLC, Chevy Chase Trust Holdings Inc., ARK Investment Management LLC, Gilder Gagnon Howe & Co. LLC, Prentiss Smith & Co. Inc., Peregrine Capital Management LLC and Russell Investments Group Ltd.. Company insiders that have sold Foundation Medicine company stock in the last year include Evan/ Fa Jones, Jason Ryan, Konstantin Fiedler, Michael J Doherty, Michael J Pellini, Robert W Hesslein, Steven J Kafka, Troy Cox and Vincent A Miller. View Insider Buying and Selling for Foundation Medicine.

Which major investors are buying Foundation Medicine stock?

FMI stock was purchased by a variety of institutional investors in the last quarter, including Gabelli Funds LLC, Morgan Stanley, Water Island Capital LLC, Gamco Investors INC. ET AL, Bank of America Corp DE, Chicago Capital Management LLC, GABELLI & Co INVESTMENT ADVISERS INC. and Berkley W R Corp. View Insider Buying and Selling for Foundation Medicine.

How do I buy shares of Foundation Medicine?

Shares of FMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Foundation Medicine's stock price today?

One share of FMI stock can currently be purchased for approximately $137.00.

How big of a company is Foundation Medicine?

Foundation Medicine has a market capitalization of $5.09 billion and generates $152.90 million in revenue each year. The company earns $-161,460,000.00 in net income (profit) each year or ($4.50) on an earnings per share basis. Foundation Medicine employs 662 workers across the globe.

How can I contact Foundation Medicine?

Foundation Medicine's mailing address is 150 Second Street, Cambridge MA, 02141. The company can be reached via phone at 617-418-2200 or via email at [email protected]


MarketBeat Community Rating for Foundation Medicine (NASDAQ FMI)

Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  160 (Vote Outperform)
Underperform Votes:  325 (Vote Underperform)
Total Votes:  485
MarketBeat's community ratings are surveys of what our community members think about Foundation Medicine and other stocks. Vote "Outperform" if you believe FMI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FMI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/17/2018 by MarketBeat.com Staff

Featured Article: Short Selling

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.